Enzymotec (ENZY) Misses Q2 EPS by 4c; Trims FY16 Outlook

Enzymotec (NASDAQ: ENZY) reported Q2 EPS of $0.04, $0.04 worse than the analyst estimate of $0.08. Revenue for the quarter came in at $15 million versus the consensus estimate of $14.9 million.

GUIDANCE:

Enzymotec sees FY2016 EPS of $0.25-$0.30, versus the consensus of $0.29. Enzymotec sees FY2016 revenue of $52-56 million, versus the consensus of $60.0 million.

For earnings history and earnings-related data on Enzymotec (ENZY) click here.

You May Also Be Interested In

• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance
• HA Sustainable Infrastructure Ca (HASI) PT Lowered to $45 at BofA Securities
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance